CPhI Worldwide to return in 2021

CPhI Worldwide 2021 31 August - 2 September 2021, Milan, Italy.
CPhI Worldwide will be held next year in Milan (Fiera Milano) for the first time in over a decade - following its postponement in 2020. The event returns at an apt moment, as the pharma industry in Italy is anticipated to be one of the main beneficiaries of geo-diverse sourcing strategies.

Italy is Europe's largest producer and exporter of APIs - 85% are exported to North America, the EU and Japan[1] - and the 2020 CPhI Annual Report Survey indicates the country is well set for growth in 2021, as pharma looks for new manufacturing partners. The results show that Italy has improved its 'growth ranking' by 16% in a year - the largest rise of any country - with Western European API manufacturers predicted to be the 'biggest beneficiaries of supply chain changes' by some 47% of respondents.

To further empower the industry's growth, CPhI Worldwide 2021 will implement a 'hybrid event model', featuring onsite exhibition and conference agenda, as well as online sessions and matchmaking. Offering further encouragement for the prospects of attendees, nearly two thirds (61%) of the industry foresees an improved 'business outlook for pharma' in 2021, with 67% 'actively looking for new partners'.

"We are really excited to be hosting the 2021 event in Milan - Europe's largest pharma manufacturing region - especially with Italy seeing the largest reputational and growth increases of any country in our recent executive survey. Pharma manufacturers here, and particularly ingredients producers, are widely expected to see sizable growth rates in 2021, with companies now actively looking to make new contacts, and implement multi-partner sourcing strategies. That’s why meeting new contacts at the event next year will be so important, as it will be the first time the global community has come back together," commented Orhan Caglayan, Brand Director at CPhI Worldwide/Informa.

CPhI Worldwide 2021 in Milan will feature all five co-located events; including P-MEC, FDF, ICSE, BioProduction and Innopack, with Informa's AllSecure Standards implemented - providing the most robust at-event biosafety measures, spanning dozens of special health&safety protocols.

Caglayan added: "CPhI Worldwide is international pharma’s only true one-stop-hub for everything from equipment, generics and packaging through to biologics, ingredients and contract services. We believe that quality of life can be improved through attainable healthcare, delivered by more accessible and affordable medicines. It is why over the last 30+ years we have built a platform to unite the specialist communities improving healthcare - and our role has never been more important as new supply chain partnerships are sought globally. We help accelerate pharma advancement by enabling attendees to meet with not just one or two, but hundreds of potential partners simultaneously. Nowhere else can you do this as well as at CPhI Worldwide and we cannot wait to welcome global pharma to Milan."

For further information, please visit:
https://www.cphi.com/europe/en/home.html

About CPhI

CPhI drives growth and innovation at every step of the global pharmaceutical supply chain from drug discovery to finished dosage. Through exhibitions, conferences and online communities, CPhI brings together more than 100,000 pharmaceutical professionals each year to network, identify business opportunities and expand the global market. CPhI hosts events in Europe, Korea, China, India, Japan, South East Asia, North America, and the Middle East and Africa. Co-locating with ICSE for contract services; P-MEC for machinery, equipment & technology; InnoPack for pharmaceutical packaging; bioLIVE for biopharma; Finished Dosage Formulation for every aspect of the finished dosage supply chain; and NEX for natural extract products, applications and solutions.

About Informa Markets

Informa Markets creates platforms for industries and specialist markets to trade, innovate and grow. Our portfolio is comprised of more than 550 international B2B events and brands in markets including Healthcare & Pharmaceuticals, Infrastructure, Construction & Real Estate, Fashion & Apparel, Hospitality, Food & Beverage, and Health & Nutrition, among others. We provide customers and partners around the globe with opportunities to engage, experience and do business through face-to-face exhibitions, specialist digital content and actionable data solutions. As the world's leading exhibitions organizer, we bring a diverse range of specialist markets to life, unlocking opportunities and helping them to thrive 365 days of the year.

The Informa Markets annual schedule of Pharmaceutical events include: CPhI & P-MEC China 2020 (16-18 December 2020 (Virtual)); CPhI & P-MEC India 2020 (28-29 January 2021 at the India Expo Mart, Greater Noida, Delhi NCR - Delhi, India); CPhI Japan (14-16 April, 2021 at the Big Sight Exhibition Centre - Tokyo, Japan); Pharmapack Europe 2021 (19-20 May, 2021 at the Paris Expo, Porte de Versailles - Paris, France); CPhI and P-MEC China 2021 (22-24 June, 2021 at SNIEC - Shanghai, China); CPhI South East Asia (4-6 August, 2021 at Challenger 2, IMPACT, Muang Thong Thani, Thailand); CPhI North America (10 August - 12 August, 2021 at Pennsylvania Convention Centre - Philadelphia, USA); CPhI Korea (11-13 August 2021), COEX - Seoul, Korea).CPhI, ICSE, P-MEC, FDF, InnoPack Worldwide, BioProduction (31 August - 2 September 2021 at Fiera Milano, Milan); CPhI Middle East & Africa (26-28 September, 2021 at the Riyadh International Convention & Exhibition Center, Riyadh, Saudi Arabia).

1. Italian Pharma Outlook, Tuesday 6th October at the CPhI Festival of Pharma

Most Popular Now

Lilly and Lycia Therapeutics enter into strategic …

Eli Lilly and Company (NYSE: LLY) and Lycia Therapeutics, Inc. today announced a multi-year research collaboration and licensing agreement focused on the discovery, devel...

SK bioscience and GSK start Phase 3 trial of adjuv…

SK bioscience (SK) and GlaxoSmithKline plc (GSK) today announced the initiation of a Phase 3 clinical study of SK's COVID-19 vaccine candidate, GBP510, in combination wit...

Blood vessels produce growth factor that promotes …

Blood vessels supply tumors with nutrients and, on the other hand, enable cancer cells to spread throughout the body. The settlement of circulating tumor cells in a dista...

No serious health effects linked to mRNA COVID-19 …

Federal and Kaiser Permanente researchers combing the health records of 6.2 million patients found no serious health effects that could be linked to the 2 mRNA COVID-19 v...

New study examines 'Achilles heel' of cancer tumou…

Researchers at the University of British Columbia's faculty of medicine and BC Cancer Research Institute have uncovered a weakness in a key enzyme that solid tumour cance...

AI algorithm solves structural biology challenges

Determining the 3D shapes of biological molecules is one of the hardest problems in modern biology and medical discovery. Companies and research institutions often spend ...

First-in-human clinical trial for a vaccine to tre…

The first patients have been enrolled in a phase 1 randomized placebo-controlled clinical trial to study a therapeutic vaccine for opioid use disorder developed by resear...

A drug costing less than €2 a day helps in the tre…

Metoprolol, a drug widely used to treat cardiovascular disease, is beneficial when administered to COVID-19patients. This is the finding of a study by investigators at th...

Rheumatoid arthritis treated with implanted cells …

With a goal of developing rheumatoid arthritis therapies with minimal side effects, researchers at Washington University School of Medicine in St. Louis have genetically ...

Sandoz strengthens pipeline by entering into agree…

Sandoz, a Novartis division, today announced that it has entered into a commercialization agreement with Bio-Thera Solutions, Ltd. for biosimilar bevacizumab (BAT1706). B...

Pfizer and BioNTech submit a variation to EMA with…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that they submitted a variation to the European Medicines Agency (EMA) requesting to update the Condition...

One in three Americans had COVID-19 by the end of …

A new study published in the journal Nature estimates that 103 million Americans, or 31 percent of the U.S. population, had been infected with SARS-CoV-2 by the end of 20...